Compare TRT & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | BCTX |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 28.8M |
| IPO Year | N/A | N/A |
| Metric | TRT | BCTX |
|---|---|---|
| Price | $5.60 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 82.3K | ★ 1.1M |
| Earning Date | 02-10-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $42,188,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | $163.26 | ★ N/A |
| Revenue Growth | ★ 0.10 | N/A |
| 52 Week Low | $2.31 | $4.10 |
| 52 Week High | $7.60 | $98.20 |
| Indicator | TRT | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 37.79 |
| Support Level | $5.25 | $4.20 |
| Resistance Level | $6.43 | $4.50 |
| Average True Range (ATR) | 0.43 | 0.32 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 6.67 | 9.93 |
Trio-Tech International operates in the semiconductor industry, providing manufacturing, testing, and distribution services for semiconductor test equipment and electronic components. It has two main segments: Semiconductor Back-end Solutions (SBS) and Industrial Electronics (IE). The SBS segment, which generates the majority of the Company's revenue, focuses on manufacturing equipment for semiconductor back-end processes, offering testing services, and distributing burn-in test related equipment. The IE segment manufactures equipment for other industries and distributes electronic products outside the semiconductor sector. The Company operates in the United States, Singapore, Malaysia, Thailand, and China, serving customers across multiple regions.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.